Cellerix, SL: Series C $37.7M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Crohn's, X - GI, X - Stem Cell

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2008

Genizon Biosciences, Inc.: Series D $31M

Posted in I - Series D, Q - 1Q08, R - INTERNATIONAL, X - Asthma, X - Biomarker, X - Crohn's, X - Schizophrenia

Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.

Feb

2007

ActoGeniX, NV: Series A $26M

Posted in I - Series A, R - INTERNATIONAL, X - Crohn's

ActoGeniX, (Belgium) is developing a pipeline of therapeutic products based on its TopAct™ technology platform with it’s most advanced candidate for Crohn’s disease, closed a $26M Series A led by GIMV and Life Sciences Partners. New investors include Aescap, Ventech and Baekeland Fonds.

to top of page...